Pfizer Discontinues Premarin in Canada

Pfizer will discontinue sales of its Premarin hormone therapy products in Canada following an internal review, a decision that could add pressure to the country’s supply of medicines used to manage menopause symptoms.

The US pharmaceutical company confirmed that it would no longer supply Premarin vaginal cream or its three strengths of oral tablets in Canada. The decision comes as some alternative hormone therapy products, including estradiol transdermal patches, are also experiencing supply constraints.

Pfizer Canada told Reuters that the vaginal cream had been in short supply since June and that no further batches would be supplied. The company said the withdrawal was not linked to any new safety, efficacy or quality concerns and that other treatment options remained available in Canada.

Premarin tablet stocks expected to last until mid-2027

Existing inventories of Premarin tablets in strengths of 0.3 milligrams, 0.625 mg and 1.25 mg are expected to remain available until approximately mid-2027.

However, the company cautioned that supplies could run out earlier if demand increases. The withdrawal therefore affects both the immediate availability of the vaginal cream and the longer-term availability of the oral formulations.

Premarin contains a mixture of estrogen hormones and is prescribed to manage symptoms associated with declining estrogen levels during menopause. These include vaginal dryness and painful intercourse, among other symptoms.

The company’s decision does not affect Premarin Intravenous, which is used in hospitals to treat abnormal uterine bleeding associated with hormonal imbalance.

Estradiol patch shortages add to supply concerns

The discontinuation comes against a wider backdrop of supply constraints in Canada’s menopause hormone therapy market.

On 4 November, Health Canada issued a notice stating that certain strengths of estradiol transdermal patches supplied by Bayer and Sandoz were in short supply. The regulator said intermittent shortages were expected to continue until early 2027.

The affected products include Bayer’s Climara patches and Sandoz’s Estalis, Estradot and Sandoz Estradiol Derm ranges. Health Canada attributed the supply difficulties to global challenges, including increased demand and manufacturing disruptions. Canada

The regulator said it was working with provincial and territorial governments, manufacturers and other stakeholders to monitor availability and manage the impact on patients. It also said alternatives listed in guidance developed for healthcare providers were not reported to be in shortage at the time of its notice.

The overlap between Pfizer’s Premarin withdrawal and the estradiol patch shortages creates an additional supply challenge for Canada’s menopause treatment market. The extent of the impact will depend on the availability of alternative products, the ability of manufacturers to maintain supply and the speed at which patients can access suitable treatments.

Rising demand puts focus on hormone therapy supply

Demand for menopause hormone therapy has been increasing, particularly in the United States. Prescriptions rose following the US Food and Drug Administration’s November 2025 removal of long-standing safety warnings from these treatments, Reuters reported.

The change has contributed to renewed attention on hormone therapy options and their availability. However, the Canadian supply situation also reflects manufacturing and distribution constraints affecting individual products.

For pharmaceutical manufacturers, the developments highlight the importance of maintaining reliable supply across different formulations and strengths. A shortage of one product does not necessarily mean that all treatments in the same category are unavailable, but it can increase the need for healthcare providers and pharmacies to manage substitutions and product availability.

Pfizer decision applies only to Canada

Pfizer’s latest decision is specific to Canada. The company declined to comment on the supply situation in other markets.

The development follows a separate supply disruption in India, where Pfizer suspended sales of Premarin vaginal cream in July 2026. Pfizer Limited subsequently told India’s stock exchanges that the imported product had been temporarily discontinued because of supply constraints and that it was exploring options to restore supplies.

In its July filing, Pfizer Limited said Premarin vaginal cream contributed less than 1% of its revenue and that the temporary discontinuation was not expected to have a material impact on its financial performance, business operations or profitability.

The Canadian withdrawal and the earlier Indian supply disruption are separate market developments. Pfizer has not indicated that the Canadian decision represents a global discontinuation of Premarin.

For Canada’s healthcare supply chain, attention will now turn to the availability of alternative menopause treatments and whether existing stocks of Premarin tablets last through the expected transition period.

Follow B2B Market Signal on social media for the latest business news, industry developments, market intelligence and analysis. Connect with us on LinkedIn and follow us on Instagram at @b2bmarketsignal for regular updates